NCT04297605View on ClinicalTrials.gov

Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 15, 2020

Primary Completion Date

November 30, 2025

Study Completion Date

January 30, 2026

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Pembrolizumab

Pembrolizumab 200 mg

OTHER

Pemetrexed (Chemotherapy)

500 mg/m2 day 1 of 21 day cycle (for non-squamous only)

OTHER

Nab-paclitaxel (Chemotherapy)

100 mg/m2 days 1,8 of 21 day cycle x 4 cycles

Trial Locations (1)

14642

University of Rochester, Rochester

All Listed Sponsors
lead

University of Rochester

OTHER